"Drug Labeling" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Use of written, printed, or graphic materials upon or accompanying a drug container or wrapper. It includes contents, indications, effects, dosages, routes, methods, frequency and duration of administration, warnings, hazards, contraindications, side effects, precautions, and other relevant information.
| Descriptor ID |
D004348
|
| MeSH Number(s) |
E05.916.310 J01.576.655.750.321.400 J01.576.761.300.400
|
| Concept/Terms |
Drug Labeling- Drug Labeling
- Labeling, Drug
- Drug Labelling
- Labelling, Drug
- Package Inserts, Drug
- Drug Package Insert
- Drug Package Inserts
- Insert, Drug Package
- Inserts, Drug Package
- Package Insert, Drug
- Product Labeling, Drug
- Drug Product Labeling
- Labeling, Drug Product
Black Box Warning- Black Box Warning
- Black Box Warnings
- Box Warning, Black
- Box Warnings, Black
- Warning, Black Box
- Warnings, Black Box
- Boxed Warning
- Boxed Warnings
- Warning, Boxed
- Warnings, Boxed
|
Below are MeSH descriptors whose meaning is more general than "Drug Labeling".
Below are MeSH descriptors whose meaning is more specific than "Drug Labeling".
This graph shows the total number of publications written about "Drug Labeling" by people in this website by year, and whether "Drug Labeling" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 0 | 1 |
| 2010 | 3 | 0 | 3 |
| 2011 | 1 | 4 | 5 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Labeling" by people in Profiles.
-
JAK inhibitors and black box warnings: what is the future for JAK inhibitors? Expert Rev Clin Immunol. 2023 Jul-Dec; 19(11):1385-1397.
-
Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. Oncologist. 2020 03; 25(3):e405-e411.
-
Rationale, Opportunities, and Reality of Biosimilar Medications. N Engl J Med. 2018 May 24; 378(21):2036-2044.
-
Cardiorenal Safety of OTC Analgesics. J Cardiovasc Pharmacol Ther. 2018 03; 23(2):103-118.
-
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
-
Food Effect Studies for Oncology Drug Products. Clin Pharmacol Ther. 2017 May; 101(5):606-612.
-
Capsule Commentary on Wolf et al., A Patient-Centered Prescription Drug Label to Promote Appropriate Medication Use and Adherence. J Gen Intern Med. 2016 12; 31(12):1507.
-
Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs. J Manag Care Spec Pharm. 2015 Dec; 21(12):1214-34.
-
Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. Mayo Clin Proc. 2015 Jun; 90(6):716-29.
-
Incorporating biomarkers into drug labeling. Clin Adv Hematol Oncol. 2014 Aug; 12(8):525-8.